{"id":129208,"date":"2026-09-11T03:50:11","date_gmt":"2026-09-11T03:50:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/129208\/"},"modified":"2026-09-11T03:50:11","modified_gmt":"2026-09-11T03:50:11","slug":"fda-halts-sk-biopharms-opcalim-novartis-12-billion-drug-fails-phase-3-biggo-finance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/129208\/","title":{"rendered":"FDA Halts SK Biopharm&#8217;s OPCALIM; Novartis&#8217; $12 Billion Drug Fails Phase 3 \u2014 BigGo Finance"},"content":{"rendered":"<p>The partial clinical hold imposed by the U.S. Food and Drug Administration (FDA) on OPCALIM (BHV-7000), an epilepsy drug candidate, and the Phase 3 failure of the key asset behind Novartis&#8217; $12 billion (approximately 16.1 trillion won) acquisition sent shockwaves through the global pharmaceutical and biotech industry in the same week. In contrast, AstraZeneca and Amgen delivered divergent results, confirming survival improvements in a Phase 3 trial of a combination therapy for small cell lung cancer.<\/p>\n<p>The FDA has issued a partial clinical hold on OPCALIM, an epilepsy drug candidate recently licensed by South Korea&#8217;s SK Biopharm (326030.KS), suspending new patient enrollment. Biohaven announced that the FDA notified the company of the decision on the 4th. Regulators requested additional data to evaluate the potential risk that certain metabolites identified in rodent studies could pose to humans.<\/p>\n<p>Under this action, the Phase 2 trial (RISE2) of OPCALIM has temporarily halted new patient recruitment. However, more than 600 patients already assigned to treatment arms can continue receiving the drug. According to Biohaven, OPCALIM has been administered to more than 1,200 clinical trial participants to date, and no safety signals or adverse events related to the non-clinical toxicity findings have been observed in clinical trials.<\/p>\n<p>SK Biopharm held an online briefing on the 11th to explain its position regarding the FDA action. Yoo Chang-ho, head of the Strategy Division and Business Development, who led the licensing deal, attended the briefing. &#8220;We were already fully aware of this issue before signing the contract,&#8221; Yoo said. &#8220;Through our own assessment and external experts, we determined that the likelihood of the same problem occurring in humans from the unique metabolic pathway identified in mice was low.&#8221;<\/p>\n<p>SK Biopharm signed a global exclusive license agreement with Biohaven on the 26th of last month covering the Kv7 ion channel platform, including OPCALIM. The deal is valued at up to $795 million (approximately 1.1 trillion won), including an upfront payment of $400 million (approximately 540 billion won) and development and regulatory milestones. SK Biopharm has not yet paid the upfront fee to Biohaven, and the two companies are in discussions to close the transaction after resolving the FDA issue.<\/p>\n<p>The Phase 3 trial (RISE3) of OPCALIM completed patient enrollment in June and is not directly affected by this action. SK Biopharm plans to maintain its schedule for announcing top-line results in the second half of this year. &#8220;We expect Biohaven to submit data to the FDA between late September and early October, with the issue ultimately resolved between October and November,&#8221; Yoo said. &#8220;We will proceed with contract closing after these issues are resolved.&#8221; The company is targeting a U.S. market launch as early as 2029 if clinical development proceeds as planned.<\/p>\n<p>Meanwhile, Novartis announced on the 8th (local time) that del-desiran, being developed as a treatment for myotonic dystrophy type 1 (DM1), failed to meet its primary endpoint in a global Phase 3 trial. Del-desiran is a drug candidate developed by Avidity Biosciences based on its antibody-oligonucleotide conjugate (AOC) platform.<\/p>\n<p>The trial set vHOT, a video-based measurement of the time it takes for patients to open their hand after making a fist, as the primary endpoint. However, the del-desiran treatment arm did not show statistically significant improvement compared to placebo. The failure was particularly shocking to the market because it came after Novartis acquired Avidity for $12 billion to secure del-desiran. Novartis shares fell 10.9% on the day the results were announced, erasing approximately $32 billion (approximately 43 trillion won) in market capitalization.<\/p>\n<p>Novartis plans to conduct additional analysis of the full clinical dataset before discussing future development directions with regulators. Shares of Dyne Therapeutics and Sarepta Therapeutics, which are developing candidates for the same indication, also declined in tandem, leading to assessments that the results have impacted the broader DM1 drug development landscape beyond individual candidates.<\/p>\n<p>In contrast, AstraZeneca and Amgen announced on the 8th that a combination of Imfinzi and Imdelltra met its primary endpoint in a Phase 3 trial for patients with extensive-stage small cell lung cancer (ES-SCLC).<\/p>\n<p>The trial enrolled 563 patients whose disease had not progressed after initial treatment with Imfinzi plus platinum-based chemotherapy and etoposide. Patients were randomized to either the Imfinzi plus Imdelltra combination arm or the Imfinzi monotherapy arm. Interim analysis showed that the combination arm achieved a statistically significant improvement in overall survival compared to Imfinzi alone. Improvements were also confirmed in key secondary endpoints, including progression-free survival and objective response rate.<\/p>\n<p>Imdelltra is a bispecific T-cell engager that simultaneously binds to DLL3, which is predominantly expressed on small cell lung cancer cells, and CD3 on T cells, directing immune cells to attack cancer cells. Imfinzi is currently used in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer. If these results lead to future regulatory approval, a new treatment strategy could emerge that adds Imdelltra to Imfinzi monotherapy maintenance following initial treatment.<\/p>\n<p>This week&#8217;s clinical results once again underscored the inherent uncertainty of drug development. The simultaneous announcements of FDA regulatory intervention, a Phase 3 failure of a major M&amp;A asset, and successful combination therapy data produced contrasting impacts on individual companies&#8217; development strategies and market valuations. For SK Biopharm in particular, the fact that the company proceeded with the deal despite being aware of the issue during pre-contract due diligence has drawn investor attention, and the outcome of future FDA communications along with Phase 3 top-line data are expected to be key variables in determining OPCALIM&#8217;s commercial value.<\/p>\n","protected":false},"excerpt":{"rendered":"The partial clinical hold imposed by the U.S. Food and Drug Administration (FDA) on OPCALIM (BHV-7000), an epilepsy&hellip;\n","protected":false},"author":2,"featured_media":129209,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[4498,14607,7849,62948,62199,62950,42061,206,62949,62947,14639],"class_list":["post-129208","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-amgen","tag-astrazeneca","tag-avidity-biosciences","tag-biohaven","tag-del-desiran","tag-imdelltra","tag-imfinzi","tag-novartis","tag-opcalim","tag-sk-biopharm","tag-u-s-food-and-drug-administration"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117250374100353780","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/129208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=129208"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/129208\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/129209"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=129208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=129208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=129208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}